clinical phase News
-
Approval for clinical phase II study in DFU by German health agency PEI
On 27 May 2021 Aposcience AG received the notification of the Paul-Ehrlich-Institut of the approval of the clinical phase II trial in diabetic foot ulcer (DFU), MARSYAS II, for Germany. Currently, the MARSYAS II trial has regulatory approvals for Austria, Czech Republic, Germany and Poland. ...
-
We are looking for a Clinical Project Manager
Join us when we are expanding our unit with another Clinical Project Manager. In this role, you will lead the planning, execution and documentation of clinical studies for our late clinical phase vaccine products. Join us in our work to give people worldwide a longer and better life. We are an entrepreneurial company and experts in global vaccine development, manufacturing, registration and ...
-
German Federal Ministry of Education and Research („BMBF“) selects tiakis Biotech AG to develop Tiprelestat as a potential therapeutic for COVID-19.
tiakis Biotech AG (formerly Proteo Biotech AG) has announced that the German BMBF has selected the Company to conduct a clinical phase 1b/2 trial to develop its investigational medical product Tiprelestat as a potential therapeutic for COVID-19. The aim of the clinical trial is to assess Tiprelestat’s efficacy to attenuate severe disease progression of COVID-19. The Company expects the ...
-
Greenwich LifeSciences Announces Removal of Clinical Hold Permitting Phase III Clinical Trial to Proceed
Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of GLSI-100, announced that the Food and Drug Administration (FDA) has removed the clinical hold permitting the Flamingo-01 Phase III clinical trial to proceed. As previously announced, the Phase III clinical trial was placed on clinical hold by the FDA ...
-
Clinical Trial Phase I “Safety and Tolerability of Escalating Doses of Subcutaneous Elafin (Tiprelestat) Injection in Healthy Normal Subjects” completed.
tiakis Biotech AG (formerly Proteo Biotech AG) has attained another milestone in its Pulmonary Arterial Hypertension (PAH) development program by receiving the final clinical phase 1 trial report demonstrating the very good safety profile of Tiprelestat (no severe adverse occurred). tiakis’s research partners and investigators at Stanford University School of Medicine, Dr. Marlene ...
-
Showcase
A Phase Ii Trial Of Onapristone In Combination With Fulvestrant For Patients With Er-Positive And Her2-Negative Metastatic Breast Cancer After Progression On Endocrine Therapy And Cdk 4/6 Inhibitors
Antiprogestins act as Progesterone Receptor (PgR) antagonists. Novel and promising class of drugs to overcome endocrine resistance associated with ESR1 mutations. SMILE STUDY is a multi-institutional phase II clinical trial to determine the efficacy of an antiprogestin, Onapristone +fulvestrantas second line therapy for patients with HR+/HER2- metastatic breast cancer (MBC). Hypothesis: The ...
-
Prolonged Analgesia From Bupisome And Bupigel Formulations: From Design And Fabrication To Improved Stability
Based on data from early animal studies, Probudur has indicated post-operative control for up to 96 hours, which is 24 hours longer than the leading product on the market. If we are able to demonstrate a successful Phase III clinical trial, we believe Probudur may represent the first long acting local anesthetic with an opioid sparing label. ...
-
Jeanette presents E-poster at IPVC 2021
The virtual 34th International Papillomavirus Conference took place last week, from November 15-19. The conference’s theme this year was: ‘Research and education for HPV elimination’. Jeanettes E-Poster ‘A Candidate Broadly Protective HPV-Vaccine Targeting the L2 Minor Protein Demonstrates Promising Results in a Clinical Phase I Trial’ was selected for the ...
-
Update on Biosceptre’s Phase 1 Clinical Trial for First-in-Class Oncology Vaccine BIL06v
Biosceptres’ Phase I clinical trial for peptide vaccine BIL06v has now completed enrolment of the first cohort of ten patients at the first dose, and all enrolled patients have received treatment. The trial was initiated in August and, subject to a scheduled safety review this week, it is expected that recruitment of the second cohort will begin before end of November. ...
-
Adiposs starts clinical development of its flagship product ImageBAT
Adiposs SA, a Geneva-based biotech company developing medical imaging products, has successfully launched its phase 1 clinical trial on August 10, with the dosing of the first human subjects with ImageBATTM, its first-in-class product for brown fat imaging. Adiposs has initiated the clinical development of its flagship imaging product, ImageBATTM. The primary objective of the IBT001 phase 1 ...
By Adiposs
-
Cancer Targeted Technology Commences Phase I Clinica Trial of CTT1057, a Diagnostic Imaging Agent for Prostate Cancer
Cancer Targeted Technology (CTT), a privately-held Seattle-based biotechnology firm focusing on small molecules that target pivotal enzyme targets on cancer, announced that a Phase I clinical trial has commenced in men with high risk metastatic prostate cancer. In late August, the Food and Drug Administration cleared CTT’s first Investigational New Drug Application (IND) for a Positron ...
-
Infant Bacterial Therapeutics publishes Annual Report for 2021
Infant Bacterial Therapeutics AB (publ) publishes today the Annual Report for 2021. The report is available on IBT’s website ibtherapeutics.com under the section “Investors & Media – Financial Reports” and is available in printed form for those that have requested. A copy can be requested by contacting IBT’s office via info@ibtherapeutics.com. About Infant ...
-
Lattice Medical announces the success of the first breast reconstruction operation with the Mattisse implant
After the entry into clinical phase announced in early July 2022, LATTICE MEDICAL, announces the success of the first breast reconstruction operation with the MATTISSE implant. The operation took place on July 12 at the Institute of Clinical Oncology, Tbilisi, Georgia. It was conducted by Pr Gia Nemsdaze and his team, and in the presence of the co-founders of Lattice Medical, Pr. Pierre ...
-
Dr David Dantzker to present Origin’s plasma-generated Nitric Oxide to the MEIDAM dermatology conference in Dubai on September 21, 2019
Origin, Inc., a Phase III clinical-stage biotechnology company, today announced that Dr. David Dantzker, Vice Chairman and Chief Medical Officer of Origin, and former Chairman of the American Board of Internal Medicine, would be presenting Origin’s plasma-generated Nitric Oxide technology to The 4th Middle East International Dermatology & Aesthetic Medicine Conference & Exhibition ...
By Origin, Inc
-
Recruitment of the smallest infants in the Connection study paused
IBT started to recruit infants in Strata A (weight of 500g-749g) in The Connection Study on April 29 2021. Today, 68 infants have been recruited to the group. In accordance with the study protocol and clinical observations, enrolment of infants to Strata A has been paused awaiting a safety review by the Data Monitoring Committee (DMC). Subjects already randomized will continue treatment as per ...
-
Showcase
POP Biotechnologies Vaccine Technology to Enter Phase III Clinical Studies as part of Eubiologics’ COVID-19 Vaccine Candidate, EuCorVac-19
POP Biotechnologies (POP BIO), a Buffalo, NY based biopharmaceutical startup, announces the approval of the plan for a phase 3 clinical study of EuCorVac-19, a COVID-19 vaccine candidate developed by South Korean partner EuBiologics (KOSDAQ: 206650, CEO, Dr. Baik YoungOk, Mr. Seukkeun Choi) from the Ministry of Food and Drug Safety in South Korea. EuCorVac-19, is a protein-based vaccine ...
-
Cabaletta Bio Reports Top-line Biologic Activity Data from Two Lowest Dose Cohorts in DesCAARTes™ Trial in Patients with Mucosal Pemphigus Vulgaris
PHILADELPHIA, Dec. 14, 2021 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today reported top-line data on biologic activity from the two lowest dose cohorts in the DesCAARTes™ Phase 1 clinical trial of DSG3-CAART for ...
-
Starton Therapeutics Provides Update on STAR-LLD Lenalidomide Clinical Program
Starton Therapeutics Inc., a clinical stage biotechnology company provides updates on its first-in-human Phase 1 STAR-LLD clinical trial of its investigational continuous delivery lenalidomide, in healthy subjects. Four subjects in the first cohort received 24 hours of STAR-LLD continuous lenalidomide, and a single oral dose of lenalidomide after a 24 hour washout period. The Independent Data ...
-
Cabaletta Bio Reports Clinical Data from the Second Dose Cohort in DesCAARTes™ Trial in Patients with mPV
PHILADELPHIA, Aug. 18, 2021 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today announced 28-day data from the second dose cohort, at the 100 million cell dose level, in the DesCAARTes™ Phase 1 clinical trial of ...
-
Gesynta Pharma initiates clinical phase I study with GS-248 for the treatment of microvascular disease
Gesynta Pharma AB ("Gesynta") announces that the first clinical study with GS-248 has been initiated and that the first healthy volunteers have been dosed. The purpose of the phase I study is to study safety, tolerability and pharmacokinetic properties of GS-248 as well as its effect on relevant biomarkers. Gesynta's lead candidate drug, GS-248, is a potent and selective inhibitor of ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you